EUR 0.08
(6.38%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 14.35 Million EUR | 12.46% |
2022 | 12.76 Million EUR | 76.36% |
2021 | 7.23 Million EUR | -6.06% |
2020 | 7.7 Million EUR | -19.43% |
2019 | 9.56 Million EUR | 60385.71% |
2018 | 15.81 Thousand EUR | -23.8% |
2017 | 20.75 Thousand EUR | 3.63% |
2016 | 20.02 Thousand EUR | 184.07% |
2015 | 7049.20 EUR | -99.86% |
2014 | 5.1 Million EUR | 51.37% |
2013 | 3.37 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 Q4 | 7294.20 EUR | 0.0% |
2023 FY | 15.2 Million EUR | 19.12% |
2023 Q2 | 7.63 Million EUR | 0.0% |
2022 Q4 | 6.77 Million EUR | 0.0% |
2022 FY | 12.76 Million EUR | 76.36% |
2022 Q2 | 5.99 Million EUR | 0.0% |
2021 Q4 | 3.3 Million EUR | 0.0% |
2021 Q2 | 3.93 Million EUR | 0.0% |
2021 FY | 7.23 Million EUR | -6.06% |
2020 FY | 7.7 Million EUR | -19.43% |
2020 Q4 | 3.91 Million EUR | 0.0% |
2020 Q2 | 3.76 Million EUR | 0.0% |
2019 FY | 9.56 Million EUR | 60385.71% |
2019 Q4 | 4.91 Million EUR | 0.0% |
2019 Q2 | 4.64 Million EUR | 0.0% |
2018 Q4 | 6127.20 EUR | 0.0% |
2018 Q2 | 9685.00 EUR | 0.0% |
2018 FY | 15.81 Thousand EUR | -23.8% |
2017 Q4 | 9498.30 EUR | 0.0% |
2017 Q2 | 11.25 Thousand EUR | 0.0% |
2017 FY | 20.75 Thousand EUR | 3.63% |
2016 Q4 | 10.68 Thousand EUR | 0.0% |
2016 FY | 20.02 Thousand EUR | 184.07% |
2016 Q2 | 9342.30 EUR | 0.0% |
2015 Q2 | 2218.30 EUR | 0.0% |
2015 FY | 7049.20 EUR | -99.86% |
2015 Q4 | 4830.90 EUR | 0.0% |
2014 Q3 | 7725.00 EUR | 288.72% |
2014 Q1 | 7725.00 EUR | 0.0% |
2014 Q2 | 1987.30 EUR | -74.27% |
2014 FY | 5.1 Million EUR | 51.37% |
2014 Q4 | 3106.90 EUR | -59.78% |
2013 FY | 3.37 Million EUR | 0.0% |
2013 Q1 | 4300.00 EUR | 0.0% |
2013 Q3 | 4300.00 EUR | 0.0% |
2013 Q4 | 7725.00 EUR | 79.65% |
2013 Q2 | 4300.00 EUR | 0.0% |
2012 Q4 | 4300.00 EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -243.723% |
ABIVAX Société Anonyme | 127.37 Million EUR | 88.728% |
Adocia SA | 15.62 Million EUR | 8.137% |
Aelis Farma SA | 18.81 Million EUR | 23.708% |
Biophytis S.A. | 14.33 Million EUR | -0.17% |
Advicenne S.A. | 8.21 Million EUR | -74.769% |
genOway Société anonyme | 16.73 Million EUR | 14.225% |
IntegraGen SA | 5.35 Million EUR | -168.235% |
Medesis Pharma S.A. | 1.56 Million EUR | -817.65% |
Neovacs S.A. | 10.34 Million EUR | -38.804% |
NFL Biosciences SA | 4.37 Million EUR | -228.215% |
Plant Advanced Technologies SA | 2.76 Million EUR | -419.28% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -735.716% |
Sensorion SA | 27.05 Million EUR | 46.93% |
Theranexus Société Anonyme | 3 Million EUR | -377.782% |
TME Pharma N.V. | 5.49 Million EUR | -161.184% |
Valbiotis SA | 9.86 Million EUR | -45.479% |
TheraVet SA | 1.64 Million EUR | -773.149% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 29.344% |
argenx SE | 1.34 Billion EUR | 98.931% |
BioSenic S.A. | 7.58 Million EUR | -89.335% |
Celyad Oncology SA | 8.49 Million EUR | -69.108% |
DBV Technologies S.A. | 89.4 Million EUR | 83.941% |
Galapagos NV | 327.98 Million EUR | 95.623% |
Genfit S.A. | 54.8 Million EUR | 73.802% |
Hyloris Pharmaceuticals SA | 17.98 Million EUR | 20.18% |
Innate Pharma S.A. | 64.57 Million EUR | 77.765% |
Inventiva S.A. | 120.18 Million EUR | 88.054% |
MaaT Pharma SA | 21.59 Million EUR | 33.525% |
MedinCell S.A. | 32.92 Million EUR | 56.39% |
Nanobiotix S.A. | 58.92 Million EUR | 75.635% |
Onward Medical N.V. | 20.64 Million EUR | 30.456% |
Oryzon Genomics S.A. | 18.49 Million EUR | 22.381% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 39.136% |
Oxurion NV | 12.21 Million EUR | -17.548% |
Pharming Group N.V. | 204.24 Million EUR | 92.971% |
Poxel S.A. | 28.76 Million EUR | 50.088% |
GenSight Biologics S.A. | 32.66 Million EUR | 56.04% |
Transgene SA | 31.23 Million EUR | 54.029% |
Financière de Tubize SA | 114.38 Thousand EUR | -12451.294% |
UCB SA | 2.94 Billion EUR | 99.512% |
Valneva SE | 134.92 Million EUR | 89.359% |
Vivoryon Therapeutics N.V. | 24.69 Million EUR | 41.854% |